Ever since troglitazone was pulled from the market because of hepatotoxicity,clinicians has been concerned that this may be a class effect. But a newstudy of rosiglitazone (Avandia), funded by manufacturer SmithKlineBeecham,indicates this drug is not associated with heptatotoxic effects.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Liver toxicity risk low with rosiglitazone

Newsletter